Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 4/20 | 0.54 |
| ▸ | PGR | P06401 | 2/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.54 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.54 |
| ▸ | IDO1 | P14902 | 2/20 | 0.54 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.54 |
| ▸ | TACR2 | P21452 | 2/20 | 0.54 |
| ▸ | DRD1 | P21728 | 2/20 | 0.54 |
| ▸ | ACHE | P22303 | 2/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.54 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.54 |
| ▸ | HTR2A | P28223 | 2/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11076935 | 0.91 | LMNA (0.53) | CYP2C9PGRCHRM2CYP3A4ADRA2A | |
| SCHEMBL9748629 | 0.84 | CYP19A1 (0.62) | CYP2C9PGRCHRM2CYP3A4ADRA2A | |
| SCHEMBL11255215 | 0.84 | LMNA (0.50) | CYP2C9PGRCHRM2CYP3A4ADRA2A | |
| SCHEMBL20551987 | 0.83 | CYP2C9 (0.51) | CYP2C9PGRCHRM2CYP3A4ADRA2A | |
| SCHEMBL10352849 | 0.83 | ALDH1A1 (0.51) | CYP2C9PGRCHRM2CYP3A4ADRA2A | |
| SCHEMBL11273740 | 0.82 | LMNA (0.54) | CYP2C9CYP3A4CYP2D6CYP2C19LMNA | |
| SCHEMBL11708365 | 0.81 | HMOX1 (0.61) | CYP2C9PGRCHRM2CYP3A4ADRA2A | |
| SCHEMBL11607374 | 0.81 | ALDH1A1 (0.57) | CYP3A4CYP2D6TBXAS1CYP19A1LMNA | |
| SCHEMBL11070453 | 0.80 | CYP2C9 (0.57) | CYP2C9PGRCHRM2CYP3A4ADRA2A | |
| SCHEMBL8444354 | 0.80 | LMNA (0.58) | CYP2C9PGRCHRM2CYP3A4ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5591726-A | Heterocyclylalkyl diarylboron ester and thioester fungicidal agents | AMERICAN CYANAMID COMPANY (US) | 1997-01-07 | — | — | US | claimed |
| US-12590963-B2 | Anti-cancer treatment of preselected subjects and screening methods to identify susceptible subjects | TUDAG TU DRESDEN AKTIENGESELLSCHAFT (DE) | 2026-03-31 | — | — | US | disclosed |
| EP-3803402-B1 | ANTI-CANCER TREATMENT OF PRESELECTED SUBJECTS AND SCREENING METHODS TO IDENTIFY SUSCEPTIBLE SUBJECTS | TUDAG TU DRESDEN AG (DE) | 2023-04-26 | — | — | EP | disclosed |
| EP-3578981-B1 | ANTI-CANCER TREATMENT OF PRESELECTED SUBJECTS AND SCREENING METHODS TO IDENTIFY SUSCEPTIBLE SUBJECTS | TUDAG TU DRESDEN AG (DE) | 2021-10-27 | — | — | EP | disclosed |
| US-20210231661-A1 | ANTI-CANCER TREATMENT OF PRESELECTED SUBJECTS AND SCREENING METHODS TO IDENTIFY SUSCEPTIBLE SUBJECTS | TUDAG TU DRESDEN AKTIENGESELLSCHAFT (DE) | 2021-07-29 | — | — | US | disclosed |
| EP-3803402-A1 | ANTI-CANCER TREATMENT OF PRESELECTED SUBJECTS AND SCREENING METHODS TO IDENTIFY SUSCEPTIBLE SUBJECTS | Tudag Tu Dresden Aktiengesellschaft (DE) | 2021-04-14 | — | — | EP | disclosed |
| CN-112534265-A | Screening method for preselecting individual for anti-cancer treatment and identifying individual susceptible to disease | TUDAG德累斯顿工业大学股份公司 | 2021-03-19 | — | — | CN | disclosed |
| WO-2019233779-A1 | ANTI-CANCER TREATMENT OF PRESELECTED SUBJECTS AND SCREENING METHODS TO IDENTIFY SUSCEPTIBLE SUBJECTS | Technische Universität Dresden (DE) | 2019-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12590963-B2 | Anti-cancer treatment of preselected subjects and screening methods to identify susceptible subjects | TPM4, TPM3, TAGLN2 | CYP2C9 793/4885PGR 918/4885CHRM2 2458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.